Use of antipsychotics and long-term risk of parkinsonism

Neurol Sci. 2022 Apr;43(4):2545-2553. doi: 10.1007/s10072-021-05650-z. Epub 2021 Oct 15.

Abstract

Introduction: Few epidemiological studies have assessed the risk of parkinsonisms after prolonged use of neuroleptics. We aimed to examine the long-term risk of degenerative parkinsonisms (DP) associated with previous use of neuroleptics.

Methods: All residents in Piedmont, Northern-west Italy, older than 39 years (2,526,319 subjects), were retrospectively followed up from 2013 to 2017. Exposure to neuroleptics was assessed through the regional archive of drug prescriptions. The development of DP was assessed using the regional archives of both drug prescriptions and hospital admissions. We excluded prevalent DP cases at baseline as well as those occurred in the first 18 months (short-term risk). The risk of DP associated with previous use of neuroleptics was examined through Cox regression, using a matched cohort design.

Results: The risk of DP was compared between 63,356 exposed and 316,779 unexposed subjects. A more than threefold higher risk of DP was observed among subjects exposed to antipsychotics, compared to those unexposed (HR = 3.27, 95% CI 3.00-3.57), and was higher for exposure to atypical than typical antipsychotics. The risk decreased after 2 years from therapy cessation but remained significantly elevated (HR = 2.38, 95% CI 1.76-3.21).

Conclusions: These results indicate a high risk of developing DP long time from the start of use and from the cessation for both typical and atypical neuroleptics, suggesting the need of monitoring treated patients even after long-term use and cessation.

Keywords: Atypical parkinsonisms; Drug-induced parkinsonism; Epidemiology; Neuroleptics; Parkinson’s disease.

MeSH terms

  • Antipsychotic Agents* / adverse effects
  • Cohort Studies
  • Hospitalization
  • Humans
  • Parkinsonian Disorders* / chemically induced
  • Parkinsonian Disorders* / drug therapy
  • Parkinsonian Disorders* / epidemiology
  • Retrospective Studies

Substances

  • Antipsychotic Agents